Angina Pectoris Drugs Market Growth and Trends: Key Insights into Market Opportunities for 2025-2034
2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!
Which Major Market Drivers Are Expected to Boost the Growth Potential of the Angina Pectoris Drugs Market?
The angina pectoris drug market’s expansion is likely to be boosted by the rising prevalence of cardiovascular diseases. These diseases cover an array of ailments affecting the heart and blood vessels, such as coronary artery disease, high blood pressure, heart failure, and stroke. The escalating incidence of cardiovascular diseases (CVD) can be linked to various factors, like an aging population, unhealthy lifestyle choices, and the surge in obesity. Angina pectoris medications, like nitrates, beta-blockers, and calcium channel blockers, effectively alleviate chest pain and unease resulting from inadequate blood flow to the heart, thereby improving the overall well-being of the patients. For instance, the British Heart Foundation, a cardiovascular research charity based in the UK, reported in September 2024 that approximately 7.6 million people in the UK suffer from heart and circulatory diseases, including roughly 4 million males and 3.6 million females. These diseases account for approximately 27% of all fatalities in the UK, resulting in more than 170,000 deaths per year, or about 480 deaths daily, equating to a death every three minutes. Thus, the escalading prevalence of cardiovascular diseases is fostering the growth of the angina pectoris drug market.
Get Your Free Sample Report Now – Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10797&type=smp
#What Growth Opportunities Will Drive the Angina Pectoris Drugs Market’s CAGR Through 2034?
The market size for angina pectoris medications has seen robust growth in past years. The market, estimated to be worth $12.32 billion in 2024, is projected to increase to $12.94 billion in 2025, marking a compound annual growth rate (CAGR) of 5.1%. Factors contributing to this growth during the historical period include a high incidence rate of cardiovascular ailments, the aging demographic, lifestyle patterns, an uptick in hypertension instances, and the pervasiveness of diabetes.
In the coming years, the market size for angina pectoris drugs is poised for substantial growth, with projections indicating a rise to $16.55 billion in 2029 at a Compound Annual Growth Rate (CAGR) of 6.3%. The predicted expansion in this timeframe is due to factors such as the increasing worldwide obesity rates, advancements in precision medicine, an emphasis on preventive cardiology, efforts to educate patients, and research into new therapeutic targets. Other significant trends expected within this period are the use of telemedicine for distance monitoring, real-world evidence and results studies, patient-focused medication tutelage, strategic alliances for market entry, regulatory advancements, and fast-track approvals.
You can Directly Purchase the Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10797
What Are the Key Market Innovations in theAngina Pectoris Drugs Market Over the Coming Years?
The rise of product innovation is a significant trend being observed in the angina pectoris drugs market. Major firms in the sector are turning to cutting-edge technologies to maintain their market stance. To illustrate, Hikma Pharmaceuticals PLC, a UK-based pharmaceutical firm, introduced Labetalol Hydrochloride Injection, USP, in a prefilled syringe in March 2023. This product is approved by the US Food and Drug Administration. The 10 mg/2 mL PFS version of the medication is used in hospitals to manage severe hypertension and reduce blood pressure.
Who Are the Top Companies Driving Innovation and Growth in theAngina Pectoris Drugs Market?
Major companies operating in the angina pectoris drugs market include Astellas Pharma Inc., Bayer AG, Novartis AG, AstraZeneca PLC, Bausch Health Companies Inc., Merck & Co Inc., Eli Lilly and Company, Pfizer Inc., Abbott Laboratories, Sun Pharmaceutical Industries Limited, Sanofi SA, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Johnson & Johnson, AERIE PHARMACEUTICALS INC., AbbVie Inc., Amgen Inc., Gilead Sciences Inc., GlaxoSmithKline plc, H. Lundbeck A/S, Ipsen S.A., Lupin Pharmaceuticals Inc., Merck KGaA, Otsuka Pharmaceutical Co. Ltd., Regeneron Pharmaceuticals Inc., Servier Laboratories, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB S.A.
Order Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report
Which Key Market Segments Comprise the Angina Pectoris Drugs Market and Drive Its Revenue Growth?
The angina pectoris drugs market covered in this report is segmented –
1) By Drugs: Nitrates, Antiplatelet Agents, Beta-adrenergic Blocking Agents, Calcium Channel Blockers, Anti-ischemic Agents, Statins, Antihypertensive Agents, Other Drugs
2) By Indication: Stable Angina, Unstable Angina, Prinzmetal’s Angina
3) By Route of Administration: Oral, Parenteral, Transdermal, Other Route Of Administrations
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Nitrates: Short-Acting Nitrates, Long-Acting Nitrates
2) By Antiplatelet Agents: Aspirin, Clopidogrel
3) By Beta-Adrenergic Blocking Agents: Non-Selective Beta Blockers, Selective Beta Blockers
4) By Calcium Channel Blockers: Dihydropyridine Calcium Channel Blockers, Non-dihydropyridine Calcium Channel Blockers
5) By Anti-Ischemic Agents: Ranolazine, Ivabradine
6) By Statins: Atorvastatin, Rosuvastatin
Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=10797&type=smp
Which Regions Are Emerging as Leaders in the Angina Pectoris Drugs Market?
North America was the largest region in the angina pectoris drugs market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the angina pectoris drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Browse Through More Reports Similar to the Gobal Angina Pectoris Drugs Maret 2025, By The Business Research Company:
Alzheimer’s Drugs Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/alzheimers-drugs-global-market-report
Generic Central Nervous System Drugs Global Market Report 2024
Tumor Necrosis Factor Inhibitor Drugs Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
